Cargando…

PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study

BACKGROUND: Although the phenotype of polycystic ovary syndrome (PCOS) is heterogeneous, there is paucity of data on the prevalence and phenotype of PCOS in sub-Saharan Africa. METHODS: We studied 75 consecutive consenting women, aged 18-45 years, who presented with features suggestive of PCOS. A st...

Descripción completa

Detalles Bibliográficos
Autores principales: Balogun, Mobolanle, Coker, Olayinka, Samuel, Titilola, Sluss, Patrick, Udenze, Christiana, Azziz, Ricardo, Makwe, Christian Chigozie, Olamijulo, Joseph Ayo, Akinkugbe, Ayesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627323/
http://dx.doi.org/10.1210/jendso/bvac150.1436
_version_ 1784822940795142144
author Balogun, Mobolanle
Coker, Olayinka
Samuel, Titilola
Sluss, Patrick
Udenze, Christiana
Azziz, Ricardo
Makwe, Christian Chigozie
Olamijulo, Joseph Ayo
Akinkugbe, Ayesha
author_facet Balogun, Mobolanle
Coker, Olayinka
Samuel, Titilola
Sluss, Patrick
Udenze, Christiana
Azziz, Ricardo
Makwe, Christian Chigozie
Olamijulo, Joseph Ayo
Akinkugbe, Ayesha
author_sort Balogun, Mobolanle
collection PubMed
description BACKGROUND: Although the phenotype of polycystic ovary syndrome (PCOS) is heterogeneous, there is paucity of data on the prevalence and phenotype of PCOS in sub-Saharan Africa. METHODS: We studied 75 consecutive consenting women, aged 18-45 years, who presented with features suggestive of PCOS. A standardized proforma was used to obtain relevant information. Anthropometric measurements were determined, and terminal hair growth was assessed using the modified Ferriman-Gallwey (mF-G) method. All subjects underwent an oral glucose tolerance test (OGTT) and pelvic ultrasonography on day 2-7 of the menstrual cycle. An mF-G score of ≥ 6 was regarded as evidence of clinical hyperandrogenism (HA). Menstrual dysfunction (MD) was defined as menstrual cycle lengths >35 or <25 days. Polycystic Ovarian Morphology (PCOM) was defined as an antral follicle count (AFC) of ≥12 2-9 mm follicles and/or an ovarian volume ≥10 cm3, in at least one ovary. RESULTS: The mean (SD) age of the study population was 28.6 (5.8) years, and the mean (SD) body mass index (BMI) was 26.3 (5.6) kg/m2. Three (4.0%) participants were underweighted, 27 (36.0%) had normal BMI, 30 (40%) were overweight, and 15 (20.0%) were obese. The mean (SD) systolic and diastolic blood pressures were 107.4 (12.6) mmHg and 72.6 (8.2) mmHg, respectively. OGTT results indicated that the mean (SD) fasting blood glucose was 86.6 (10.6) mg/dl and the mean (SD) 2-hr. postprandial glucose was 109.8 (22.2) mg/dl. Two women had impaired glucose tolerance and one had type 2 diabetes mellitus. Of the 75 subjects recruited, 26 (34.7%) had HA, 54 (72.0%) had MD, and 63 (84.0%) had PCOM. Of all subjects, 20 (26.7%) had HA+MD+PCOM, consistent with PCOS Phenotype A; one (1.3%) had HA+MD only, consistent with Phenotype B; four (5.3%) had HA+PCOM only, consistent with Phenotype C; and 28 (37.3%) had MD+PCOM only, consistent with Phenotype D. In 22 (29.4%) no evidence of PCOS was found. Overall, our results indicate that of subjects evaluated clinically, 53 (70.6%) had PCOS. CONCLUSIONS: Our preliminary results indicate that in a referral (clinical) population in Lagos, Nigeria, using only the clinical presentation without circulating androgen measures, PCOS was detected in two-thirds, with Phenotype D (aka, 'non-hyperandrogenic PCOS’) being the most common presentation (53%), followed by Phenotype A (aka 'classic or full PCOS’) observed in 38% of all women with PCOS seen. However, as 72% of all subjects had MD and 63% had PCOM, many more of these women could have been diagnosed with PCOS if the presence of hyperandrogenemia could have been demonstrated. Overall, these observations suggest that accurate measurement of circulating androgen, lacking in many parts of Sub-Sahara Africa, may be critical to accurately detecting PCOS in that region. Studies are ongoing. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.
format Online
Article
Text
id pubmed-9627323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96273232022-11-03 PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study Balogun, Mobolanle Coker, Olayinka Samuel, Titilola Sluss, Patrick Udenze, Christiana Azziz, Ricardo Makwe, Christian Chigozie Olamijulo, Joseph Ayo Akinkugbe, Ayesha J Endocr Soc Reproductive Endocrinology BACKGROUND: Although the phenotype of polycystic ovary syndrome (PCOS) is heterogeneous, there is paucity of data on the prevalence and phenotype of PCOS in sub-Saharan Africa. METHODS: We studied 75 consecutive consenting women, aged 18-45 years, who presented with features suggestive of PCOS. A standardized proforma was used to obtain relevant information. Anthropometric measurements were determined, and terminal hair growth was assessed using the modified Ferriman-Gallwey (mF-G) method. All subjects underwent an oral glucose tolerance test (OGTT) and pelvic ultrasonography on day 2-7 of the menstrual cycle. An mF-G score of ≥ 6 was regarded as evidence of clinical hyperandrogenism (HA). Menstrual dysfunction (MD) was defined as menstrual cycle lengths >35 or <25 days. Polycystic Ovarian Morphology (PCOM) was defined as an antral follicle count (AFC) of ≥12 2-9 mm follicles and/or an ovarian volume ≥10 cm3, in at least one ovary. RESULTS: The mean (SD) age of the study population was 28.6 (5.8) years, and the mean (SD) body mass index (BMI) was 26.3 (5.6) kg/m2. Three (4.0%) participants were underweighted, 27 (36.0%) had normal BMI, 30 (40%) were overweight, and 15 (20.0%) were obese. The mean (SD) systolic and diastolic blood pressures were 107.4 (12.6) mmHg and 72.6 (8.2) mmHg, respectively. OGTT results indicated that the mean (SD) fasting blood glucose was 86.6 (10.6) mg/dl and the mean (SD) 2-hr. postprandial glucose was 109.8 (22.2) mg/dl. Two women had impaired glucose tolerance and one had type 2 diabetes mellitus. Of the 75 subjects recruited, 26 (34.7%) had HA, 54 (72.0%) had MD, and 63 (84.0%) had PCOM. Of all subjects, 20 (26.7%) had HA+MD+PCOM, consistent with PCOS Phenotype A; one (1.3%) had HA+MD only, consistent with Phenotype B; four (5.3%) had HA+PCOM only, consistent with Phenotype C; and 28 (37.3%) had MD+PCOM only, consistent with Phenotype D. In 22 (29.4%) no evidence of PCOS was found. Overall, our results indicate that of subjects evaluated clinically, 53 (70.6%) had PCOS. CONCLUSIONS: Our preliminary results indicate that in a referral (clinical) population in Lagos, Nigeria, using only the clinical presentation without circulating androgen measures, PCOS was detected in two-thirds, with Phenotype D (aka, 'non-hyperandrogenic PCOS’) being the most common presentation (53%), followed by Phenotype A (aka 'classic or full PCOS’) observed in 38% of all women with PCOS seen. However, as 72% of all subjects had MD and 63% had PCOM, many more of these women could have been diagnosed with PCOS if the presence of hyperandrogenemia could have been demonstrated. Overall, these observations suggest that accurate measurement of circulating androgen, lacking in many parts of Sub-Sahara Africa, may be critical to accurately detecting PCOS in that region. Studies are ongoing. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9627323/ http://dx.doi.org/10.1210/jendso/bvac150.1436 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Balogun, Mobolanle
Coker, Olayinka
Samuel, Titilola
Sluss, Patrick
Udenze, Christiana
Azziz, Ricardo
Makwe, Christian Chigozie
Olamijulo, Joseph Ayo
Akinkugbe, Ayesha
PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title_full PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title_fullStr PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title_full_unstemmed PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title_short PMON245 Clinical Phenotypes of Polycystic Ovary Syndrome (PCOS) in Nigerian Women: Preliminary Results of the Nigeria PCOS Epidemiology & Phenotype (Nigeria-Pep) Study
title_sort pmon245 clinical phenotypes of polycystic ovary syndrome (pcos) in nigerian women: preliminary results of the nigeria pcos epidemiology & phenotype (nigeria-pep) study
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627323/
http://dx.doi.org/10.1210/jendso/bvac150.1436
work_keys_str_mv AT balogunmobolanle pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT cokerolayinka pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT samueltitilola pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT slusspatrick pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT udenzechristiana pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT azzizricardo pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT makwechristianchigozie pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT olamijulojosephayo pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy
AT akinkugbeayesha pmon245clinicalphenotypesofpolycysticovarysyndromepcosinnigerianwomenpreliminaryresultsofthenigeriapcosepidemiologyphenotypenigeriapepstudy